Eva M. Marco

Dr. Eva M. Marco


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
MVM Viveros
M Viveros
EMEva M. Marco
Eva M. Marco
SFS File
S File

7 July 2010 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
EMEva M. Marco
Eva M. Marco
SMSimone Macrì
Simone Macrì
Giovanni LaviolaGiovanni Laviola
Giovanni Laviola

4 September 2003 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
MBMiguel Biscaia
Miguel Biscaia
SMSusana Marín
Susana Marín
BFBeatriz Fernández
Beatriz Fernández
EMEva M. Marco
Eva M. Marco
MRMarina Rubio
Marina Rubio
MVMaria-Paz Viveros
Maria-Paz Viveros

1 April 2015 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
EMEva M. Marco
Eva M. Marco
RLRicardo Llorente
Ricardo Llorente
MGMeritxell López Gallardo
Meritxell López Gallardo
VMVirginia Mela
Virginia Mela
ÁLÁlvaro Llorente-Berzal
Álvaro Llorente-Berzal
MVMaria-Paz Viveros
Maria-Paz Viveros

1 February 2004 in Behavioural Pharmacology
Verified
Journal Article
Closed access
EMEva M. Marco
Eva M. Marco
LPL Pérez-Alvarez
L Pérez-Alvarez
EBE Borcel
E Borcel
MRMarina Rubio
Marina Rubio
CGC Guaza
C Guaza
MVMaria-Paz Viveros
Maria-Paz Viveros
We have studied the possible interaction between the cannabinoid receptor agonist CP 55,940 (1 and 50 μg/kg) and the 5-HT1A receptor antagonist WAY 100635 (1 mg/kg) in the modulation of plus-maze and holeboard activity in Wistar adult male rats. In the plus-maze, the higher dose of CP 55,940 induced an anxiogenic-like effect, whereas the lower dose induced anxiolytic-like responses. The 5-HT1A antagonist, which was silent in this test, attenuated the anxiogenic, but not the anxiolytic, effect of CP 55,940. In the holeboard, the higher dose of CP 55,940 significantly decreased head-dipping duration, and WAY 100635, which did not affect exploratory head-dipping when administered alone, antagonized this effect. The administration of WAY 100635 significantly increased grooming behaviour, and this effect was inhibited by the two doses of CP 55,940, which did not exert any effect, per se, on this parameter. We provide the first evidence implicating 5-HT1A receptors in anxiety-related behavioural responses to a cannabinoid agonist.

1 May 2013 in Neuropharmacology
Verified
Journal Article
Closed access
EMEva M. Marco
Eva M. Marco
MVManuel Valero
Manuel Valero
OSOscar de la Serna
Oscar de la Serna
BABarbara Aisa
Barbara Aisa
EBErika Borcel
Erika Borcel
MVMaria-Paz Viveros
Maria-Paz Viveros